Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

1.

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.

Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP.

Cancer Res. 2011 Oct 15;71(20):6503-13. doi: 10.1158/0008-5472.CAN-11-0532. Epub 2011 Aug 25.

PMID:
21868758
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.

Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB.

Clin Cancer Res. 2011 Sep 15;17(18):5913-25. doi: 10.1158/1078-0432.CCR-11-0728. Epub 2011 Aug 1.

PMID:
21807635
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis.

Kumagai J, Hofland J, Erkens-Schulze S, Dits NF, Steenbergen J, Jenster G, Homma Y, de Jong FH, van Weerden WM.

Prostate. 2013 Nov;73(15):1636-50. doi: 10.1002/pros.22655. Epub 2013 Sep 2.

PMID:
23996639
[PubMed - indexed for MEDLINE]
4.

Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.

Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP.

Oncogene. 2014 May 29;33(22):2815-25. doi: 10.1038/onc.2013.235. Epub 2013 Jun 10. Review.

PMID:
23752196
[PubMed - indexed for MEDLINE]
5.

Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.

Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, Jenster G, Schröder FH, de Jong FH.

Cancer Res. 2010 Feb 1;70(3):1256-64. doi: 10.1158/0008-5472.CAN-09-2092. Epub 2010 Jan 19.

PMID:
20086173
[PubMed - indexed for MEDLINE]
Free Article
6.

Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.

Cai C, Balk SP.

Endocr Relat Cancer. 2011 Aug 30;18(5):R175-82. doi: 10.1530/ERC-10-0339. Print 2011 Oct. Review.

PMID:
21712345
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Sharifi N.

Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Review.

PMID:
20524793
[PubMed - indexed for MEDLINE]
8.

Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.

Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W, de Bono JS.

J Clin Endocrinol Metab. 2012 Feb;97(2):507-16. doi: 10.1210/jc.2011-2189. Epub 2011 Dec 14.

PMID:
22170708
[PubMed - indexed for MEDLINE]
9.

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J.

Cancer Res. 2012 Jul 15;72(14):3457-62. doi: 10.1158/0008-5472.CAN-11-3892. Epub 2012 Jun 18.

PMID:
22710436
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.

Evaul K, Li R, Papari-Zareei M, Auchus RJ, Sharifi N.

Endocrinology. 2010 Aug;151(8):3514-20. doi: 10.1210/en.2010-0138. Epub 2010 Jun 9.

PMID:
20534728
[PubMed - indexed for MEDLINE]
11.

Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.

Li R, Evaul K, Sharma KK, Chang KH, Yoshimoto J, Liu J, Auchus RJ, Sharifi N.

Clin Cancer Res. 2012 Jul 1;18(13):3571-9. doi: 10.1158/1078-0432.CCR-12-0908.

PMID:
22753664
[PubMed - indexed for MEDLINE]
Free Article
12.

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC.

Cancer Res. 2008 Aug 1;68(15):6407-15. doi: 10.1158/0008-5472.CAN-07-5997.

PMID:
18676866
[PubMed - indexed for MEDLINE]
Free Article
13.

Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.

Yamaoka M, Hara T, Hitaka T, Kaku T, Takeuchi T, Takahashi J, Asahi S, Miki H, Tasaka A, Kusaka M.

J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):115-28. doi: 10.1016/j.jsbmb.2012.01.001. Epub 2012 Jan 12.

PMID:
22249003
[PubMed - indexed for MEDLINE]
14.

Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.

Vis AN, Schröder FH.

BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. Review.

PMID:
19558559
[PubMed - indexed for MEDLINE]
15.

Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer.

Yamaoka M, Hara T, Kusaka M.

Clin Cancer Res. 2010 Sep 1;16(17):4319-24. doi: 10.1158/1078-0432.CCR-10-0255. Epub 2010 Jul 20. Review.

PMID:
20647476
[PubMed - indexed for MEDLINE]
Free Article
16.

Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.

Locke JA, Guns ES, Lehman ML, Ettinger S, Zoubeidi A, Lubik A, Margiotti K, Fazli L, Adomat H, Wasan KM, Gleave ME, Nelson CC.

Prostate. 2010 Feb 15;70(3):239-51. doi: 10.1002/pros.21057.

PMID:
19790237
[PubMed - indexed for MEDLINE]
17.

Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.

Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB.

PLoS One. 2012;7(1):e30062. doi: 10.1371/journal.pone.0030062. Epub 2012 Jan 18.

PMID:
22279565
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.

Pham S, Deb S, Ming DS, Adomat H, Hosseini-Beheshti E, Zoubeidi A, Gleave M, Guns ES.

J Steroid Biochem Mol Biol. 2014 Oct;144 Pt B:436-44. doi: 10.1016/j.jsbmb.2014.09.004. Epub 2014 Sep 6.

PMID:
25201454
[PubMed - in process]
19.

The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer.

Sharifi N.

J Investig Med. 2012 Feb;60(2):504-7. doi: 10.231/JIM.0b013e31823874a4. Review.

PMID:
22064602
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.

Thelen P, Heinrich E, Bremmer F, Trojan L, Strauss A.

Prostate. 2013 Nov;73(15):1699-709. doi: 10.1002/pros.22711. Epub 2013 Jul 19.

PMID:
23868789
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk